ResearcherTokai UniversityActive in the last 2 years
Shigenori Ei
Matched on ORCID iD 0000-0002-3233-1635; OpenAlex author ID A5073117366. Sources: OpenAlex.
Their work
- Papers
- 5
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 28
2023: 3 papers · 2024: 1 paper · 2025: 1 paper
Papers 5
- Low Pretreatment CALLY Index Predicts Early Recurrence in Resected UICC Stage I Pancreatic Ductal Adenocarcinoma. Co-author PMID 40105230↗
- Metavert synergises with standard cytotoxics in human PDAC organoids and is associated with transcriptomic signatures of therapeutic response. Co-author DOI 10.1016/j.tranon.2024.102109↗
- Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC. Co-author DOI 10.1038/s43018-023-00628-6↗
- Induction Chemotherapy with FOLFIRINOX for Locally Advanced Pancreatic Cancer: A Simple Scoring System to Predict Effect and Prognosis. Co-author DOI 10.1245/s10434-022-12569-y↗
- Neoadjuvant and Adjuvant Treatments for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: The Current Status of Pancreatic Ductal Adenocar… Co-author DOI 10.5009/gnl220311↗
Closest collaborators
The 25 strongest of 28 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Toshio Nakagohri · 2 shared papers, 2023–2025 · strength 0.47
- Shinichiro Takahashi · 2 shared papers, 2023–2025 · strength 0.47
- Taro Mashiko · 2 shared papers, 2023–2025 · strength 0.47
- Thilo Hackert · 3 shared papers, 2023–2024 · strength 0.47
- Paper Induction Chemotherapy with FOLFIRINOX for Locally Advanced Pancreatic Cancer: A Simple Scoring System to Predict Effec… DOI 10.1245/s10434-022-12569-y↗
- Paper Metavert synergises with standard cytotoxics in human PDAC organoids and is associated with transcriptomic signatures o… DOI 10.1016/j.tranon.2024.102109↗
- Paper Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC. DOI 10.1038/s43018-023-00628-6↗
- Markus Wolfgang Büchler · 2 shared papers, 2023 · strength 0.32
- Ulrike Heger · 2 shared papers, 2023 · strength 0.32
- Peter J. Bailey · 2 shared papers, 2023–2024 · strength 0.27
- Paper Metavert synergises with standard cytotoxics in human PDAC organoids and is associated with transcriptomic signatures o… DOI 10.1016/j.tranon.2024.102109↗
- Paper Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC. DOI 10.1038/s43018-023-00628-6↗
- Jingyu An · 2 shared papers, 2023–2024 · strength 0.27
- Paper Metavert synergises with standard cytotoxics in human PDAC organoids and is associated with transcriptomic signatures o… DOI 10.1016/j.tranon.2024.102109↗
- Paper Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC. DOI 10.1038/s43018-023-00628-6↗
- Franco Fortunato · 2 shared papers, 2023–2024 · strength 0.27
- Paper Metavert synergises with standard cytotoxics in human PDAC organoids and is associated with transcriptomic signatures o… DOI 10.1016/j.tranon.2024.102109↗
- Paper Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC. DOI 10.1038/s43018-023-00628-6↗
- Christoph Springfeld · 2 shared papers, 2023–2024 · strength 0.27
- Paper Metavert synergises with standard cytotoxics in human PDAC organoids and is associated with transcriptomic signatures o… DOI 10.1016/j.tranon.2024.102109↗
- Paper Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC. DOI 10.1038/s43018-023-00628-6↗
- Xu Zhou · 2 shared papers, 2023–2024 · strength 0.27
- Paper Metavert synergises with standard cytotoxics in human PDAC organoids and is associated with transcriptomic signatures o… DOI 10.1016/j.tranon.2024.102109↗
- Paper Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC. DOI 10.1038/s43018-023-00628-6↗
- John P. Neoptolemos · 2 shared papers, 2023–2024 · strength 0.27
- Paper Metavert synergises with standard cytotoxics in human PDAC organoids and is associated with transcriptomic signatures o… DOI 10.1016/j.tranon.2024.102109↗
- Paper Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC. DOI 10.1038/s43018-023-00628-6↗
- Masaki Mori · 1 shared paper, 2025 · strength 0.26
- Ulla Klaiber · 1 shared paper, 2023 · strength 0.19
- Masayuki Tanaka · 1 shared paper, 2023 · strength 0.19
- André L. Mihaljević · 1 shared paper, 2023 · strength 0.19
- Max Heckler · 1 shared paper, 2023 · strength 0.19
- Susanne Roth · 1 shared paper, 2024 · strength 0.14
- Martin Loos · 1 shared paper, 2024 · strength 0.14
- Georg Beyer · 1 shared paper, 2024 · strength 0.14
- Julia V. Mayerle · 1 shared paper, 2024 · strength 0.14
- Stephen Jacob Pandol · 1 shared paper, 2024 · strength 0.14
- Christoph W. Michalski · 1 shared paper, 2024 · strength 0.14
- Mouad Edderkaoui · 1 shared paper, 2024 · strength 0.14
- Nicolas Hohmann · 1 shared paper, 2023 · strength 0.13
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.